MX2010005950A - 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors. - Google Patents
2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors.Info
- Publication number
- MX2010005950A MX2010005950A MX2010005950A MX2010005950A MX2010005950A MX 2010005950 A MX2010005950 A MX 2010005950A MX 2010005950 A MX2010005950 A MX 2010005950A MX 2010005950 A MX2010005950 A MX 2010005950A MX 2010005950 A MX2010005950 A MX 2010005950A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- methods
- fluoropyrazolo
- pyrimidines
- protein kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Pyrazolo[1,5-a]pyrimidine-based inhibitors of various kinase, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions that contain such inhibitors are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 or CHK-1 inhibitor compounds, methods of inhibiting CDK-2 or CHK-1, and methods for treating disease or disease symptoms.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99073607P | 2007-11-28 | 2007-11-28 | |
PCT/US2008/084643 WO2009070567A1 (en) | 2007-11-28 | 2008-11-25 | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010005950A true MX2010005950A (en) | 2010-06-17 |
Family
ID=40343608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010005950A MX2010005950A (en) | 2007-11-28 | 2008-11-25 | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors. |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2225247A1 (en) |
JP (1) | JP2011504931A (en) |
CN (1) | CN101970440A (en) |
CA (1) | CA2706946A1 (en) |
MX (1) | MX2010005950A (en) |
WO (1) | WO2009070567A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE037716T2 (en) | 2008-10-22 | 2018-09-28 | Array Biopharma Inc | Substituted pyrazolo[1,5-]pyrimidine compounds as trk kinase inhibitors |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
MY191934A (en) | 2010-05-20 | 2022-07-19 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
DK2941432T3 (en) | 2012-12-07 | 2018-06-14 | Vertex Pharma | 2-amino-6-fluoro-N- (5-fluoro-4- (4- (4- (oxetan-3-yl) piperazine-1-carbonyl) piperidin-1-yl) pyridine-3-yl) pyrazolo [ 1,5ALPHA] PYRIMIDIN-3-CARBOXAMIDE AS ATR-KINASE INHIBITOR |
JP2016512816A (en) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2016512815A (en) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Condensed pyrazolopyrimidine derivatives useful as inhibitors of ATR kinase |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2015097121A1 (en) | 2013-12-23 | 2015-07-02 | Norgine B.V. | Compounds useful as ccr9 modulators |
SG11201610197XA (en) | 2014-06-05 | 2017-01-27 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
RS59054B1 (en) | 2014-06-17 | 2019-08-30 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
WO2016071216A1 (en) | 2014-11-03 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Piperidinylpyrazolopyrimidinones and their use |
WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US10570135B2 (en) | 2014-11-06 | 2020-02-25 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders |
SI3699181T1 (en) | 2014-11-16 | 2023-06-30 | Array Biopharma, Inc. | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
DK3233839T3 (en) * | 2014-12-19 | 2019-12-09 | Janssen Pharmaceutica Nv | HETEROCYCLYL-COUPLED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3K-BETA INHIBITORS |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
CA3020310A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
AU2017246455B2 (en) | 2016-04-06 | 2021-09-30 | Bial - R&D Investments, S.A. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
AU2017261291C1 (en) | 2016-05-05 | 2022-05-26 | Bial - R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
ES2952056T3 (en) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide |
TW201825499A (en) | 2016-09-19 | 2018-07-16 | 德商拜耳作物科學股份有限公司 | Fused bicyclic heterocycle derivatives as pesticides |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
EP4114528A1 (en) * | 2020-03-06 | 2023-01-11 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
WO2021246095A1 (en) * | 2020-06-01 | 2021-12-09 | ユニマテック株式会社 | Fluorine-containing fused ring pyrimidine compound and method for producing same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550470B2 (en) * | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
JP4564485B2 (en) * | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | Pyrazolo [1,5-a] pyrimidine derivatives |
US20080139581A1 (en) * | 2005-03-02 | 2008-06-12 | Basf Aktiengesellschaft | 2-Substituted 7-Aminoazolopyrimidines, Processes For Their Preparation And Their Use For Controlling Harmful Fungi, And Compositions Comprising These Compounds |
-
2008
- 2008-11-25 WO PCT/US2008/084643 patent/WO2009070567A1/en active Application Filing
- 2008-11-25 EP EP08854702A patent/EP2225247A1/en not_active Withdrawn
- 2008-11-25 CN CN2008801257650A patent/CN101970440A/en active Pending
- 2008-11-25 MX MX2010005950A patent/MX2010005950A/en not_active Application Discontinuation
- 2008-11-25 JP JP2010536116A patent/JP2011504931A/en not_active Withdrawn
- 2008-11-25 CA CA2706946A patent/CA2706946A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009070567A1 (en) | 2009-06-04 |
EP2225247A1 (en) | 2010-09-08 |
CN101970440A (en) | 2011-02-09 |
JP2011504931A (en) | 2011-02-17 |
CA2706946A1 (en) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010005950A (en) | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors. | |
HK1116349A1 (en) | Pyrrolopyrimidines useful as inhibitors of protein kinase | |
TW200801008A (en) | Protein kinase inhibitors | |
ZA200702645B (en) | Diaminotriazole compounds useful as protein kinase inhibitors | |
MXPA06010904A (en) | Tricyclic pyrazole kinase inhibitors. | |
TW200736249A (en) | Aminopyrimidines useful as kinase inhibitors | |
MX2009003734A (en) | Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor. | |
NO20072567L (en) | Triazoles useful as protein kinase inhibitors | |
WO2006050109A3 (en) | Novel kinase inhibitors | |
TW200745128A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
GEP20125368B (en) | Kinase inhibitors | |
MX2009012066A (en) | Substituted imidazopyridazines as pi3k lipid kinase inhibitors. | |
TW200745127A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
MX2008005398A (en) | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer. | |
TW200745123A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
MX2009006690A (en) | Aminopyrimidines useful as inhibitors of protein kinases. | |
TW200514776A (en) | Aminotriazole compounds useful as inhibitors of protein kinases | |
WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
MX2009005144A (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors. | |
IL200793A0 (en) | Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases | |
ECSP088906A (en) | PIRAZOLO 1,5-a PYRIMIDINS | |
MX2009004623A (en) | Imidazopyridazines as pi3k lipid kinase inhibitors. | |
MX2009003733A (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors. | |
MX2009004771A (en) | Tricyclic heteroaryl compounds useful as inhibitors of janus kinase. | |
WO2005076854A3 (en) | Pyrimidinone compounds useful as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |